Annual CFO
-$474.81 M
-$94.34 M-24.80%
December 31, 2023
Summary
- As of February 7, 2025, RARE annual cash flow from operations is -$474.81 million, with the most recent change of -$94.34 million (-24.80%) on December 31, 2023.
- During the last 3 years, RARE annual CFO has fallen by -$342.59 million (-259.10%).
- RARE annual CFO is now -8051.18% below its all-time high of -$5.83 million, reached on December 31, 2011.
Performance
RARE Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$67.00 M
+$9.97 M+12.95%
September 30, 2024
Summary
- As of February 7, 2025, RARE quarterly cash flow from operations is -$67.00 million, with the most recent change of +$9.97 million (+12.95%) on September 30, 2024.
- Over the past year, RARE quarterly CFO has increased by +$50.88 million (+43.16%).
- RARE quarterly CFO is now -176.70% below its all-time high of $87.35 million, reached on June 30, 2020.
Performance
RARE Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$418.59 M
+$50.88 M+10.84%
September 30, 2024
Summary
- As of February 7, 2025, RARE TTM cash flow from operations is -$418.59 million, with the most recent change of +$50.88 million (+10.84%) on September 30, 2024.
- Over the past year, RARE TTM CFO has increased by +$62.66 million (+13.02%).
- RARE TTM CFO is now -6551.66% below its all-time high of -$6.29 million, reached on March 31, 2013.
Performance
RARE TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
RARE Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -24.8% | +43.2% | +13.0% |
| 3 y3 years | -259.1% | -12.3% | -20.7% |
| 5 y5 years | -63.4% | +24.3% | -21.2% |
RARE Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -40.2% | at low | -23.3% | +64.9% | -41.0% | +17.7% |
| 5 y | 5-year | -259.1% | at low | -176.7% | +64.9% | -216.6% | +17.7% |
| alltime | all time | -8051.2% | at low | -176.7% | +64.9% | -6551.7% | +17.7% |
Ultragenyx Pharmaceutical Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$67.00 M(-13.0%) | -$418.59 M(-10.8%) |
| Jun 2024 | - | -$76.96 M(-59.6%) | -$469.47 M(-7.7%) |
| Mar 2024 | - | -$190.73 M(+127.3%) | -$508.67 M(+7.1%) |
| Dec 2023 | -$474.81 M(+24.8%) | -$83.90 M(-28.8%) | -$474.81 M(-1.3%) |
| Sep 2023 | - | -$117.87 M(+1.5%) | -$481.24 M(+4.9%) |
| Jun 2023 | - | -$116.16 M(-25.9%) | -$458.71 M(+9.3%) |
| Mar 2023 | - | -$156.87 M(+73.6%) | -$419.81 M(+10.3%) |
| Dec 2022 | -$380.46 M(+12.3%) | -$90.34 M(-5.2%) | -$380.46 M(+10.5%) |
| Sep 2022 | - | -$95.34 M(+23.4%) | -$344.47 M(+11.6%) |
| Jun 2022 | - | -$77.26 M(-34.3%) | -$308.77 M(+4.0%) |
| Mar 2022 | - | -$117.52 M(+116.3%) | -$296.87 M(-12.3%) |
| Dec 2021 | -$338.69 M(+156.2%) | -$54.34 M(-8.9%) | -$338.69 M(-2.3%) |
| Sep 2021 | - | -$59.65 M(-8.7%) | -$346.80 M(-0.7%) |
| Jun 2021 | - | -$65.36 M(-59.0%) | -$349.12 M(+77.7%) |
| Mar 2021 | - | -$159.35 M(+155.1%) | -$196.41 M(+48.6%) |
| Dec 2020 | -$132.22 M(-61.7%) | -$62.45 M(+0.8%) | -$132.22 M(-6.8%) |
| Sep 2020 | - | -$61.97 M(-170.9%) | -$141.81 M(-15.8%) |
| Jun 2020 | - | $87.35 M(-191.8%) | -$168.35 M(-51.2%) |
| Mar 2020 | - | -$95.15 M(+32.1%) | -$344.76 M(-0.2%) |
| Dec 2019 | -$345.38 M(+18.9%) | -$72.04 M(-18.6%) | -$345.38 M(+4.9%) |
| Sep 2019 | - | -$88.51 M(-0.6%) | -$329.20 M(+6.2%) |
| Jun 2019 | - | -$89.06 M(-7.0%) | -$309.85 M(+4.4%) |
| Mar 2019 | - | -$95.78 M(+71.5%) | -$296.86 M(+2.2%) |
| Dec 2018 | -$290.57 M | -$55.85 M(-19.2%) | -$290.57 M(-8.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$69.16 M(-9.1%) | -$316.54 M(+2.3%) |
| Jun 2018 | - | -$76.08 M(-15.0%) | -$309.37 M(+9.7%) |
| Mar 2018 | - | -$89.48 M(+9.4%) | -$282.12 M(+11.1%) |
| Dec 2017 | -$253.84 M(+57.7%) | -$81.82 M(+32.0%) | -$253.84 M(+15.5%) |
| Sep 2017 | - | -$61.99 M(+27.0%) | -$219.70 M(+17.8%) |
| Jun 2017 | - | -$48.82 M(-20.2%) | -$186.45 M(+5.2%) |
| Mar 2017 | - | -$61.20 M(+28.4%) | -$177.28 M(+10.1%) |
| Dec 2016 | -$160.97 M(+51.9%) | -$47.68 M(+65.9%) | -$160.97 M(+4.7%) |
| Sep 2016 | - | -$28.75 M(-27.5%) | -$153.74 M(-1.2%) |
| Jun 2016 | - | -$39.66 M(-11.7%) | -$155.59 M(+16.8%) |
| Mar 2016 | - | -$44.90 M(+11.0%) | -$133.21 M(+25.7%) |
| Dec 2015 | -$105.98 M(+137.4%) | -$40.44 M(+32.2%) | -$105.98 M(+35.9%) |
| Sep 2015 | - | -$30.60 M(+77.2%) | -$77.99 M(+33.5%) |
| Jun 2015 | - | -$17.27 M(-2.2%) | -$58.42 M(+13.1%) |
| Mar 2015 | - | -$17.66 M(+41.8%) | -$51.67 M(+15.8%) |
| Dec 2014 | -$44.63 M(+43.1%) | -$12.45 M(+12.9%) | -$44.63 M(+6.4%) |
| Sep 2014 | - | -$11.03 M(+4.8%) | -$41.95 M(+11.4%) |
| Jun 2014 | - | -$10.53 M(-0.9%) | -$37.67 M(+6.0%) |
| Mar 2014 | - | -$10.62 M(+8.7%) | -$35.53 M(+13.9%) |
| Dec 2013 | -$31.20 M(+149.5%) | -$9.77 M(+44.8%) | -$31.20 M(+45.6%) |
| Sep 2013 | - | -$6.75 M(-19.6%) | -$21.43 M(+46.0%) |
| Jun 2013 | - | -$8.39 M(+33.3%) | -$14.68 M(+133.3%) |
| Mar 2013 | - | -$6.29 M | -$6.29 M |
| Dec 2012 | -$12.50 M(+114.7%) | - | - |
| Dec 2011 | -$5.83 M | - | - |
FAQ
- What is Ultragenyx Pharmaceutical annual cash flow from operations?
- What is the all time high annual CFO for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical annual CFO year-on-year change?
- What is Ultragenyx Pharmaceutical quarterly cash flow from operations?
- What is the all time high quarterly CFO for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical quarterly CFO year-on-year change?
- What is Ultragenyx Pharmaceutical TTM cash flow from operations?
- What is the all time high TTM CFO for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical TTM CFO year-on-year change?
What is Ultragenyx Pharmaceutical annual cash flow from operations?
The current annual CFO of RARE is -$474.81 M
What is the all time high annual CFO for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high annual cash flow from operations is -$5.83 M
What is Ultragenyx Pharmaceutical annual CFO year-on-year change?
Over the past year, RARE annual cash flow from operations has changed by -$94.34 M (-24.80%)
What is Ultragenyx Pharmaceutical quarterly cash flow from operations?
The current quarterly CFO of RARE is -$67.00 M
What is the all time high quarterly CFO for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high quarterly cash flow from operations is $87.35 M
What is Ultragenyx Pharmaceutical quarterly CFO year-on-year change?
Over the past year, RARE quarterly cash flow from operations has changed by +$50.88 M (+43.16%)
What is Ultragenyx Pharmaceutical TTM cash flow from operations?
The current TTM CFO of RARE is -$418.59 M
What is the all time high TTM CFO for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high TTM cash flow from operations is -$6.29 M
What is Ultragenyx Pharmaceutical TTM CFO year-on-year change?
Over the past year, RARE TTM cash flow from operations has changed by +$62.66 M (+13.02%)